Clinical Trial Update: Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing selumetinib to placebo in differentiated thyroid cancer was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Cancer

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Differentiated Thyroid Cancer | Phase 3 | Status: TERMINATED | Results posted: 2019-04-22